Ebanga
| Chemical Name | ansuvimab-zykl |
| Dosage Form | Injection (intravenous; 400 mg lyophilized powder in a single-dose vial for reconstitution and further dilution) |
| Drug Class | Monoclonal antibodies |
| System | Blood |
| Company | Ridgeback Biotherapeutics |
| Approval Year | 2020 |
Indication
- Indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.